Interleukin-8 predicts fatigue at 12 months post-injury in children with traumatic brain injury
dc.contributor.author | Crichton, Alison | |
dc.contributor.author | Ignjatovic, Vera | |
dc.contributor.author | Babl, Franz E. | |
dc.contributor.author | Oakley, Ed | |
dc.contributor.author | Greenham, Mardee | |
dc.contributor.author | Hearps, Stephen | |
dc.contributor.author | Delzoppo, Carmel | |
dc.contributor.author | Beauchamp, Miriam | |
dc.contributor.author | Guerguerian, Anne‐Marie | |
dc.contributor.author | Boutis, Kathy | |
dc.contributor.author | Hubara, Evyatar | |
dc.date.accessioned | 2020-06-29T14:22:08Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2020-06-29T14:22:08Z | |
dc.date.issued | 2019-12-27 | |
dc.identifier.uri | http://hdl.handle.net/1866/23635 | |
dc.publisher | Mary Ann Liebert | fr |
dc.subject | Fatigue | fr |
dc.subject | Serum biomarkers | fr |
dc.subject | Children | fr |
dc.subject | Glasgow coma scale | fr |
dc.subject | GCS | fr |
dc.subject | TBI | fr |
dc.subject | Traumatic brain injury | fr |
dc.title | Interleukin-8 predicts fatigue at 12 months post-injury in children with traumatic brain injury | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté des arts et des sciences. Département de psychologie | fr |
dc.identifier.doi | 10.1089/neu.2018.6083 | |
dcterms.abstract | Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not reliably predicted persisting fatigue (up to 3 years post‐injury). This study aimed to establish if persisting fatigue is predicted by serum biomarker concentrations in child TBI. We examined if acute serum biomarker expression would improve prediction models of 12‐month fatigue based on injury severity. Blood samples were collected from 87 children (1 – 17 years at injury) sustaining mild to severe TBI (GCS range 3‐15; mean 12.43; classified as mild TBI (n=50, 57%) vs moderate/severe TBI n=37, 43%), and presenting to the Emergency Departments (ED) and Pediatric Intensive Care Units (PICU) at one of three tertiary pediatric hospitals (Royal Children’s Hospital (RCH); Hospital for Sick Children (HSC), Toronto St Justine Children’s Hospital (SJH), Montreal). Six serum biomarker concentrations were measured within 24 hours of injury [interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), soluble vascular cell adhesion molecule (SVCAM), S100 calcium binding protein B (S100B), neuron specific enolase (NSE), and soluble neural cell adhesion molecule (sNCAM)]. Fatigue at 12 months post‐injury was measured using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (parent report), classified as present/absent using previously derived cut‐points. At 12 months post‐injury, 22% of participants experienced fatigue. A model including interleukin‐8 (IL‐8) was the best serum biomarker for estimating the probability of children experiencing fatigue at 12 months post‐injury. IL‐8 also significantly improved predictive models of fatigue based on severity. | fr |
dcterms.alternative | Interleukin‐8 predict fatigue in child TBI | fr |
dcterms.isPartOf | urn:ISSN:1557-9042 | fr |
dcterms.isPartOf | urn:ISSN:0897-7151 | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | Crichton, A. J., Ignjatovic, V., Babl, F., Oakley, E., Greenham, M., Hearps, S. J., ... & Hubara, E. H. (2019). Interleukin-8 Predicts Fatigue at 12 Months Post-injury in Children with Traumatic Brain Injury. Journal of Neurotrauma, (ja). | fr |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | fr |
oaire.citationTitle | Journal of neurotrauma |
Fichier·s constituant ce document
Ce document figure dans la ou les collections suivantes
Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.